CJC-1295 Reconstitution Calculator & Guide

No. CJC-1295 is not an FDA-approved medication. FDA has stated that available clinical data are limited and has identified safety and product-quality concerns in the compounding context.

The original CJC-1295 studied in the scientific literature uses an albumin-binding Drug Affinity Complex, or DAC, that creates a prolonged half-life. The phrase 'CJC-1295 no DAC' is commonly used online for shorter-acting GHRH analog products, but naming is inconsistent and those products should not automatically be assumed to be the same compound studied in the original CJC-1295 trials.

In published studies of the original long-acting CJC-1295 compound, the estimated half-life was approximately 5.8 to 8.1 days. That figure should not be automatically applied to products marketed online as 'CJC-1295 no DAC.'

Yes. Small human studies found sustained, dose-dependent increases in endogenous growth hormone after administration of the original long-acting CJC-1295 compound.

Yes. Human pharmacology studies found sustained increases in circulating IGF-1 after long-acting CJC-1295, including increases lasting beyond the immediate GH response.

There is not strong clinical evidence establishing CJC-1295 as an effective muscle-building treatment. Human studies primarily measured GH and IGF-1 responses rather than validated gains in muscle mass or athletic performance.

Fat-loss claims are common in online discussions, but published human CJC-1295 studies have not established it as an effective weight-loss or fat-loss treatment.

They are often discussed together because CJC-1295 acts through GHRH signaling while Ipamorelin acts through the ghrelin receptor. The popularity of the combination in online communities does not establish that the combination is safe or effective for physique, recovery, or anti-aging goals.

The overall human safety profile is not well established. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction. Compounded peptide products may also raise concerns involving immunogenicity, impurities, aggregation, and product characterization.

Yes. CJC-1295 is specifically listed by WADA as a prohibited growth hormone-releasing factor and is prohibited at all times for athletes covered by WADA rules.

A vial may be labeled in milligrams, while smaller mathematical quantities can be expressed in micrograms. One milligram equals 1,000 micrograms.

Divide the labeled vial amount by the liquid volume. For example, 2mg divided by 2mL equals 1mg/mL, which is also 1,000mcg/mL. This is concentration math rather than a recommendation for how CJC-1295 should be prepared.

Yes. Enter a labeled vial amount and liquid volume to calculate concentration, equivalent liquid volume, U-100 syringe units, and approximate amounts per vial. BACToBasics provides educational math rather than medical or dosing advice.